---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061084"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:50:44.558842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Equillium Q3 net loss narrows to $3.7M; lupus trial meets endpoints

## Summary
- Net loss $3.7M ($0.11 per share) vs $13.7M loss in Q3 2022, driven by $8.9M revenue from Ono partnership.
- Cash $46.3M provides runway into 2025; net cash used in ops only $1.9M in Q3.
- EQUALISE lupus nephritis data: 73% median UPCR reduction at Week 28; 40% CR, 33% PR; safety favorable.
- Ono option decision triggered by data deliverables in early 2024; exercise would bring ~$33M payment.
- EQ101 alopecia areata fully enrolled; initial data expected Q4 2023; EQ102 SAD/MAD data also Q4.

## SEC filing metadata
- accession: 0000950170-23-061084
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017023061084/0000950170-23-061084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017023061084/eq-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061084
- JSON: https://secwatch.observer/filing/0000950170-23-061084.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.